Log in Subscribe

Consequences of intestinal GLUT2 deletion in GLUT2ΔIEC mice were limiting body weight gain despite normal food intake, improving glucose tolerance, and increasing ketone body production

Cantu Sherman
· 3 min read
Consequences of intestinal GLUT2 deletion in GLUT2ΔIEC mice were limiting body weight gain despite normal food intake, improving glucose tolerance, and increasing ketone body production

These features were reminiscent of calorie restriction. Other adaptations to intestinal GLUT2 deletion were reduced microvillus length and altered gut microbiota composition, which was associated with improved inflammatory status. Moreover, a reduced density of glucagon-like peptide-1 (GLP-1) positive cells was compensated by increased GLP-1 content per L-cell, suggesting a preserved enteroendocrine CONCLUSIONS: Intestinal GLUT2 modulates glucose absorption and constitutes a control step for the distribution of dietary sugar to tissues. Consequently, metabolic and gut homeostasis are improved in the absence of functional GLUT2 in the intestine, thus mimicking calorie restriction.5014. Nihon Rinsho.

1999 57 Suppl:323-5.High estradiol levels during a long agonist IVF protocol are associated with decreased food intake, higher leptin concentrations, and lower levels of University of Eastern Finland, Puijonlaaksontie 2, 70210, Kuopio, Finland. Finland, Kuopio Campus, P.O. Box 1627, 70211, Kuopio, Finland.University of Eastern Finland, Puijonlaaksontie 2, 70210, Kuopio, Finland.Hospital and University of Eastern Finland, Puijonlaaksontie 2, 70210, Kuopio, University Hospital, Puijonlaaksontie 2, 70210, Kuopio, Finland.

Hospital, PO Box 140, 00029, Helsinki, Finland.PURPOSE: To study whether different hormonal phases affect appetite regulation, food intake, and concentrations of leptin, glucagon-like peptide-1 (GLP-1), and high-sensitivity C-reactive protein (hs-CRP) during a long agonist in vitro METHODS: Fifty-four infertile women were encountered thrice, the first of which was at the beginning of their period (low estradiol).  glucagon-like peptide 1  were during a gonadotrophin-releasing hormone (GnRH) analog downregulation (low estradiol) and at the end of a follicle-stimulating hormone (FSH) stimulation (high estradiol). The first visit was the reference; the women served as their controls. The concentrations of leptin, GLP-1, and hs-CRP were assessed from plasma. Dietary intake was assessed using food records (FRs). In addition, weight, height, body mass index (BMI), and plasma levels of estradiol, glucose, HbA1c, insulin, and lipids were monitored.

Twenty-six of the subjects also had a RESULTS: During the stimulation protocol, leptin concentrations elevated (P < 001), and energy intake decreased (P = 03), while estradiol levels increased (P < 001). GLP-1 levels unchanged (P = 05) and hs-CRP (P = 03) concentrations diminished, while estradiol levels increased.CONCLUSION: No increased food intake or weight gain occurred during the stimulation protocol; thus, leptin may protect from overeating during high estradiol levels, and leptin resistance may not occur during a short follow-up. Also, a favorable anti-inflammatory effect was detected. During this study, we observed no harmful metabolic effects, which might affect negatively maternal Conflict of interest statement: None of the authors have competing interests.Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.University Health Science Center, Beijing, China; Department of Preventive Medicine, College of Medicine, Shihezi University, Shihezi, China.

University Health Science Center, Beijing, China.University Health Science Center, Beijing, China; Shantou-Oxford Clinical Research Unit, Shantou University Medical College, Guangdong, China.University Health Science Center, Beijing, China; Department of Statistics, Graduate School of Arts and Sciences, Columbia University, New York, New York.University Health Science Center, Beijing, China. Electronic address: PURPOSE: The goal of this study was to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on lipid profiles in patients with type METHODS: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.

The weighted mean difference for changes in lipid profiles was estimated by using the random effects model, and a network meta-analysis was performed to supplement direct FINDINGS: Thirty-five trials with 13 treatments were included in the analysis. GLP-1 RAs decreased HDL-C with a range of -06 mmol/L (95% CI, -01 to -01) to -03 mmol/L (95% CI, -07 to -00) compared with thiazolidinediones, whereas thiazolidinediones were associated with a significant increase in HDL-C compared with placebo (09 mmol/L [95% CI, 06 to 02]). A significant reduction in LDL-C was detected for all GLP-1 RAs versus placebo (range, -08 to -06 mmol/L), insulin (range, -00 to -09 mmol/L), and thiazolidinediones (range, -06 to -04 mmol/L). Exenatide, liraglutide 1 mg once daily, and taspoglutide decreased total cholesterol with a range of -06 mmol/L (95% CI, -06 to -06) to -07 mmol/L (95% CI, -01 to -02) versus placebo and thiazolidinediones (range, -06 to -07 mmol/L).  semaglutide mechanism of action  decreased effect was more evident in exenatide long-acting release and liraglutide 1 mg once daily.